Literature DB >> 23229500

Prostate cancer: Bone density testing--essential or extraneous?

Evan Y Yu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23229500     DOI： 10.1038/nrurol.2012.240

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  7 in total

1.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Authors:  M R Smith; F J McGovern; A L Zietman; M A Fallon; D L Hayden; D A Schoenfeld; P W Kantoff; J S Finkelstein
Journal:  N Engl J Med       Date:  2001-09-27       Impact factor: 91.245

2.  Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.

Authors:  Evan Y Yu; Kevin F Kuo; Roman Gulati; Shu Chen; Teresa E Gambol; Suzanne P Hall; Peter Y Jiang; Peggy Pitzel; Celestia S Higano
Journal:  J Clin Oncol       Date:  2012-04-09       Impact factor: 44.544

3.  Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.

Authors:  Alicia K Morgans; Matthew R Smith; A James O'Malley; Nancy L Keating
Journal:  Cancer       Date:  2012-10-12       Impact factor: 6.860

4.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Authors:  M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

5.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

6.  Skeletal fractures negatively correlate with overall survival in men with prostate cancer.

Authors:  Michael G Oefelein; Vincent Ricchiuti; William Conrad; Martin I Resnick
Journal:  J Urol       Date:  2002-09       Impact factor: 7.450

7.  Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Authors:  Jacques Planas; Enrique Trilla; Carles Raventós; Lluis Cecchini; Anna Orsola; Carles Salvador; Jose Placer; Gloria Encabo; Juan Morote
Journal:  BJU Int       Date:  2009-06-22       Impact factor: 5.588
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.